|
Bedford Laboratories Begins Shipping Sumatriptan Succinate Injection
Bedford, OH - February 25, 2009 - Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Sumatriptan Succinate Injection. This product is AP rated and equivalent to Imitrex® by GlaxoSmithKline. Sumatriptan is a vascular headache suppressant indicated for 1) the acute treatment of migrane attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan Succinate Injection is not for use in the management of hemiplegic or basilar migrane. "As part of our continuing strategy to expand our product portfolio, Bedford Laboratories is once again pleased to offer this very important product," said David Gaugh, Vice President of Bedford Laboratories. Bedford Laboratories will supply Sumatriptan Succinate Injection as a sterile aqueous solution in a 6mg (base) / 0.5mL single-dose vial packaged in cartons containing 10 vials. Prescribing information is available upon request from Bedford Laboratories' professional services department at 1-800-521-5169, or from the company's website, www.bedfordlabs.com. Imitrex® is a registered trademark of GlaxoSmithKline |
